In 1971, a group of researchers founded the Monash IVF Research Program with the mission to discover how in vitro fertilization, or IVF, techniques could become a treatment for infertility in both men and women. The program included researcher Carl Wood and colleagues John Leeton, Alex Lopata, Alan Trounson, and Ian Johnston at the Queen Victoria Medical Center and Royal Women’s Hospital in Melbourne, Australia. Since the program’s establishment in 1971, the Monash IVF Research Program has helped to develop and implement many IVF technologies still used in clinical practice as of 2020. Additionally, the program established some of the first successful IVF pregnancies and births. As of 2020, the Monash IVF Research Program is one of Australia’s leading fertility programs and has used their technologies to help provide IVF treatment to thousands of infertile men and women.

"MicroSort, developed in 1990 by the Genetics and IVF Institute, is a form of pre-conception sex selection technology for humans. Laboratories located around the world use MicroSort technology to help couples increase their chances of conceiving a child of their desired sex. MicroSort separates male sperm cells based on which sex chromosome they contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the same sex chromosome. The technology ultimately enables couples to choose the sex of their future child by choosing semen samples that predominately contain sperm with the X chromosome for a female or Y chromosome for a male. MicroSort technology is a sperm sorting technique that provides couples worldwide a means of pre-conception sex selection.

Ovarian hyperstimulation syndrome, abbreviated OHSS, is an atypical reaction that women may experience in response to excessive hormones, and often occurs during fertility treatments. OHSS is typically triggered by hormonal medications designed to mature eggs in the ovaries, which can cause blood vessels within the ovaries to leak fluid. Sometimes that can lead to painful tenderness or swelling. In severe cases of OHSS, that fluid can leak into the abdominal cavity in large amounts, causing vomiting, blood clots, and severe pain. As many as one out of three women undergoing fertility treatment will experience some form of OHSS, although more severe presentations are rare. While the exact cause of OHSS is not fully understood as of 2020, researchers continue to discover various risk factors, prevention techniques, and treatments that may lead to decreased risks associated with OHSS and better fertility outcomes.

Alan Osborne Trounson is a scientist from Australia who studies embryology and stem cells. His research has improved the success rates of in vitro fertilization, or IVF. IVF is a medical procedure in which scientists fertilize an egg cell with sperm outside of the body, often in a laboratory petri dish, then transfer the fertilized egg to a woman’s uterus to start pregnancy. Trounson also researched embryonic stem cells, or stem cells collected from embryos, and their potential for treating injuries and diseases. Additionally, Trounson led the Californian Institute for Regenerative Medicine, or CIRM, one of the largest agencies to fund stem cell research in California, from 2007 to 2014. Over the course of his career, Trounson developed several techniques that improved the effectiveness of IVF, including fertility treatments and cryopreservation, and supported stem cell research as a scientist and administrator.

In 2020, Rebecca Flyckt and colleagues published “First Birth from a Deceased Donor Uterus in the United States: From Severe Graft Rejection to Successful Cesarean Delivery,” hereafter “First Birth from a Deceased Donor,” in the American Journal of Obstetrics and Gynecology. In the article, Flyckt and colleagues explain that they performed one of the first uterus transplantations with a uterus from a deceased donor in the United States and detail how they did so successfully. All deceased donors in the study were considered brain-dead, not cardiac-dead. Uterus transplantation from a deceased donor is a surgical procedure in which a researcher transplants a healthy uterus from a brain-dead, deceased donor into a recipient with a diseased or absent uterus. Prior to 2020, researchers performed several uterus transplantations with live donors that resulted in live births, but there was only one recorded live birth from a deceased uterus donor. Flyckt and colleagues provide summary data about uterus transplantations from deceased donors and compare the efficacy of transplantations from live donors to those from deceased donors. “First Birth from a Deceased Donor” advances the techniques that can make uterus transplants from deceased donors successful, which allows people with uterine disorders the opportunity to become pregnant and have children.

In 2015, Mats Brännström and colleagues published “Livebirth after Uterus Transplantation” in the journal The Lancet. In “Livebirth after Uterus Transplantation,” Brännström and colleagues explain that they conducted one of the first uterus transplantations that resulted in a live birth, and they detail how they did so successfully. Uterus transplantations are a surgical procedure in which surgeons transplant a uterus from an eligible donor into a recipient with uterine infertility disorders, or UFIs, such as an absent or diseased uterus. Women with UFIs can neither conceive nor carry a pregnancy to term naturally, so uterus transplantations remain one of the only treatments available that offer them the possibility to become pregnant as of 2025. Prior to 2013, researchers worldwide had performed human uterus transplantations, but the procedures had not resulted in any reported live births. “Livebirth after Uterus Transplantation” shows that uterus transplantations can allow women with uterine infertility, which affects one in 500 women of reproductive age, the opportunity to experience pregnancy.

In 1924, John Burdon Sanderson Haldane, aka JBS Haldane, published Daedalus; or Science and The Future, hereafter Daedalus, which was a written version of a lecture that he gave in 1923. In his book, Haldane offers his personal predictions about what science will be able to achieve by the year 2073. He proposes that scientists will be able to perform ectogenesis, which he defines as the gestation of an organism in an artificial environment. He argues that the development of ectogenesis will help improve the human species by facilitating the selective breeding of individuals with desirable traits. Haldane’s vision of ectogenesis in Daedalus foreshadowed in vitro fertilization, or IVF, an assisted-reproductive technology in which scientists fertilize an egg in a laboratory dish, then implant the resulting embryo into a woman’s uterus where it then develops into a fetus. As of 2025, physicians deliver over 500,000 infants per year who were conceived using assisted-reproductive technologies such as IVF. Haldane’s concept of ectogenesis as he described it in Daedalus inspired both supportive and critical responses among readers and has shaped discussions about reproductive technologies down to the present day.